<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Verrica Pharmaceuticals Inc.

    Verrica Pharmaceuticals Inc.

    Verrica Pharmaceuticals Inc. is an innovative clinical-stage medical dermatology c...

    Verrica Pharmaceuticals Inc. is an innovative c...

    Filing Type:    PU
    OrthoPediatrics Corp.

    OrthoPediatrics Corp.

    OrthoPediatrics currently markets greater than 30 surgical systems that serve thre...

    OrthoPediatrics currently markets greater than ...

    Filing Type:    PU
    Repligen Corporation

    Repligen Corporation

    Repligen Corporation is a global bioprocessing company that develops and commercia...

    Repligen Corporation is a global bioprocessing ...

    Filing Type:    PU
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    Simulations Plus, Inc.

    Simulations Plus, Inc.

    Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...

    Simulations Plus, Inc. is the leading developer...

    Filing Type:    PU
    Satsuma Pharmaceuticals, Inc.

    Satsuma Pharmaceuticals, Inc.

    With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma...

    With operations in South San Francisco, CA and ...

    Filing Type:    PU
    Forty Seven, Inc.

    Forty Seven, Inc.

    Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...

    Forty Seven is a clinical-stage immuno-oncology...

    Filing Type:    PU
    GlycoMimetics, Inc.

    GlycoMimetics, Inc.

    At GlycoMimetics, we are committed to helping to make a difference in the lives of...

    At GlycoMimetics, we are committed to helping t...

    Filing Type:    PU
    PLUS THERAPEUTICS, Inc.

    PLUS THERAPEUTICS, Inc.

    PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a p...

    PLUS THERAPEUTICS is a clinical-stage pharmaceu...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.